Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | ROS1 | P08922 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 4/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25004485 | 0.94 | NOTUM (0.55) | NOTUMALKEGFRMETMAP3K7 | |
| SCHEMBL25005397 | 0.89 | MAP3K7 (0.43) | ALKEGFRFGFR4MAPK8MAPK9 | |
| SCHEMBL31147629 | 0.83 | NOTUM (0.50) | NOTUMALK | |
| SCHEMBL27237971 | 0.83 | NOTUM (0.50) | NOTUMALK | |
| SCHEMBL25005396 | 0.82 | MAP3K7 (0.44) | NOTUMALKEGFRMAPK8MET | |
| SCHEMBL29661271 | 0.81 | CDK9 (0.42) | ALKEGFRFGFR4MAPK8MAPK9 | |
| SCHEMBL26778572 | 0.81 | CDK9 (0.42) | ALKEGFRFGFR4MAPK8MAPK9 | |
| SCHEMBL30141686 | 0.81 | CCNA2 (0.41) | ALKMAPK8MAPK9MAPK10MAP3K7 | |
| SCHEMBL31147637 | 0.81 | NOTUM (0.47) | NOTUMSLC2A1 | |
| SCHEMBL27237994 | 0.81 | NOTUM (0.47) | NOTUMSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-10-17 | — | — | US | disclosed |
| EP-4382514-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-06-12 | — | — | EP | disclosed |
| EP-4371983-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | Korea Research Institute of Chemical Technology (KR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117794914-A | Pyrimidine-2, 4-diamine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient | 韩国化学研究院 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023014022-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023287130-A1 | NOVEL PYRIMIDINE-2,4-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | 한국화학연구원 | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343694-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | ERBB2, EGFR, DPYD | NOTUM 228/4885ALK 176/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.